Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich

H H Dubben; M Baumann; T Fassbender; H P Beck-Bornholdt

Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich

Standard

Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich. / Dubben, H H; Baumann, M; Fassbender, T; Beck-Bornholdt, H P.

In: STRAHLENTHER ONKOL, Vol. 168, No. 7, 01.07.1992, p. 373-82.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dubben, HH, Baumann, M, Fassbender, T & Beck-Bornholdt, HP 1992, 'Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich', STRAHLENTHER ONKOL, vol. 168, no. 7, pp. 373-82.

APA

Dubben, H. H., Baumann, M., Fassbender, T., & Beck-Bornholdt, H. P. (1992). Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich. STRAHLENTHER ONKOL, 168(7), 373-82.

Vancouver

Dubben HH, Baumann M, Fassbender T, Beck-Bornholdt HP. Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich. STRAHLENTHER ONKOL. 1992 Jul 1;168(7):373-82.

Bibtex

@article{59a5d76646a14135a96d537014861367,

title = "Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich",

abstract = "This paper provides a survey on investigations that deal with the effects of hyperfractionation. The influence of relevant parameters on treatment results is explained. Furthermore, clinically practicable hyperfractionated treatment schedules for therapy of head and neck tumours are proposed. Clinical and experimental reports reveal that with hyperfractionation two strategies can be realised: 1. Late normal tissue reactions can be reduced without changing total dose. In this case local tumour control rate remains unchanged. 2. To enhance tumour control rates a higher total dose can be administered, if late reactions were dose limiting in the reference schedule. In this case a reduced dose per fraction and an appropriately increased total dose will leave late reactions unchanged. Applying two fractions per day the dose per fraction should not exceed 1.4 Gy. Otherwise severe acute reactions could require treatment interruption. A time interval of at least six hours between fractions reduces the risk of acute and late reactions considerably.",

keywords = "Head and Neck Neoplasms, Humans, Linear Models, Radiation Injuries, Radiotherapy Dosage, Terminology as Topic, Time Factors",

author = "Dubben, {H H} and M Baumann and T Fassbender and Beck-Bornholdt, {H P}",

year = "1992",

month = jul,

day = "1",

language = "Deutsch",

volume = "168",

pages = "373--82",

journal = "STRAHLENTHER ONKOL",

issn = "0179-7158",

publisher = "Urban und Vogel",

number = "7",

}

RIS

TY - JOUR

T1 - Hyperfraktionierte Strahlentherapie von Tumoren im Kopf-Hals-Bereich

AU - Dubben, H H

AU - Baumann, M

AU - Fassbender, T

AU - Beck-Bornholdt, H P

PY - 1992/7/1

Y1 - 1992/7/1

N2 - This paper provides a survey on investigations that deal with the effects of hyperfractionation. The influence of relevant parameters on treatment results is explained. Furthermore, clinically practicable hyperfractionated treatment schedules for therapy of head and neck tumours are proposed. Clinical and experimental reports reveal that with hyperfractionation two strategies can be realised: 1. Late normal tissue reactions can be reduced without changing total dose. In this case local tumour control rate remains unchanged. 2. To enhance tumour control rates a higher total dose can be administered, if late reactions were dose limiting in the reference schedule. In this case a reduced dose per fraction and an appropriately increased total dose will leave late reactions unchanged. Applying two fractions per day the dose per fraction should not exceed 1.4 Gy. Otherwise severe acute reactions could require treatment interruption. A time interval of at least six hours between fractions reduces the risk of acute and late reactions considerably.

AB - This paper provides a survey on investigations that deal with the effects of hyperfractionation. The influence of relevant parameters on treatment results is explained. Furthermore, clinically practicable hyperfractionated treatment schedules for therapy of head and neck tumours are proposed. Clinical and experimental reports reveal that with hyperfractionation two strategies can be realised: 1. Late normal tissue reactions can be reduced without changing total dose. In this case local tumour control rate remains unchanged. 2. To enhance tumour control rates a higher total dose can be administered, if late reactions were dose limiting in the reference schedule. In this case a reduced dose per fraction and an appropriately increased total dose will leave late reactions unchanged. Applying two fractions per day the dose per fraction should not exceed 1.4 Gy. Otherwise severe acute reactions could require treatment interruption. A time interval of at least six hours between fractions reduces the risk of acute and late reactions considerably.

KW - Head and Neck Neoplasms

KW - Humans

KW - Linear Models

KW - Radiation Injuries

KW - Radiotherapy Dosage

KW - Terminology as Topic

KW - Time Factors

M3 - SCORING: Zeitschriftenaufsatz

C2 - 1496447

VL - 168

SP - 373

EP - 382

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 7

ER -